- Home
- CBNK vs PRLD Comparison
CBNK vs PRLD Comparison
Compare CBNK & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBNK | PRLD |
|---|---|---|
| Founded | 1974 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.3M | 529.1M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CBNK | PRLD |
|---|---|---|
| Price | $38.71 | $3.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.56 | $9.20 |
| AVG Volume (30 Days) | 133.0K | ★ 441.7K |
| Earning Date | 10-26-2026 | 11-11-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 60.85 | 23.21 |
| EPS | ★ 1.60 | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $9.44 | $258.83 |
| Revenue Next Year | $10.21 | N/A |
| P/E Ratio | $24.32 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $26.40 | $1.16 |
| 52 Week High | $40.70 | $6.83 |
Technical Indicators
Market Signals| Indicator | CBNK | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 30.79 |
| Support Level | $35.70 | $3.48 |
| Resistance Level | $40.70 | $4.10 |
| Average True Range (ATR) | 0.75 | 0.25 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 61.20 | 12.36 |
Price Performance
Historical ComparisonAbout CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.